Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
165,547,872
-
Total 13F shares
-
53,978,233
-
Share change
-
-2,679,883
-
Total reported value
-
$274,775,521
-
Price per share
-
$5.09
-
Number of holders
-
111
-
Value change
-
-$17,338,127
-
Number of buys
-
44
-
Number of sells
-
60
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q3 2021
As of 30 Sep 2021,
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) was held by
111 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,978,233 shares.
The largest 10 holders included
Point72 Asset Management, L.P., VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, RA CAPITAL MANAGEMENT, L.P., Candriam Luxembourg S.C.A., VICTORY CAPITAL MANAGEMENT INC, ORBIMED ADVISORS LLC, GREAT POINT PARTNERS LLC, and RTW INVESTMENTS, LP.
This page lists
111
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.